搜尋
市場行情
自選股
新聞
分析
交易工具
選股工具
掃碼下載
一鍵診股 讓投資更聰明
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
Deutsch
한국어
日本語
登入
免費註冊
搜尋
免費註冊
市場行情
/
股票
/
醫藥與醫學研究
/
生物技術與醫療研究
/
elvn
/
財務摘要
Enliven Therapeutics Inc
ELVN
添加自選
58.810
USD
+0.750
+1.29%
收盤 08-14 16:00(美東)
報價延遲15分鐘
58.820
USD
+58.820
盤後交易 08/14, 20:00 (美東)
4.31B
總市值
虧損
本益比TTM
Enliven Therapeutics Inc
58.810
+0.750
+1.29%
概覽
新聞分析
財務
股票評分
技術分析
預測
持股情況
股息
公司資料
財務摘要
利潤表
資產負債表
現金流量表
財報
公司估值
風險評估
概覽
新聞分析
財務
股票評分
技術分析
預測
持股情況
股息
公司資料
財務摘要
利潤表
資產負債表
現金流量表
財報
公司估值
風險評估
ELVN 財務數據
透過專為投資者打造的一站式數據看板,全面查看 Enliven Therapeutics Inc 的財務狀況。平台將複雜的財務報表整理為可自定義的視圖,助您更輕鬆地進行財務分析。您可以查看最新年度財務報告,也可以通過利潤表、資產負債表和現金流量表,按季度分析公司表現。借助實時財務指標,持續追蹤公司的經營狀況和市場表現更加便捷。
Enliven Therapeutics Inc 財報行事曆
最新發布
8月 5, 2026
每股收益 / 預測值
-0.49
/-0.40
營業收入 / 預測值
--
/0.00
查看即將公布的財報
報告期
FY2025 財報
營業收入(YoY)
--
--
每股收益(YoY)
-1.83
3.24%
分析師評級
BUY
2026/08/14
單季報
單季報+年報
單季報
年報
YOY
隱藏空白列
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
財務指標
每股收益
-0.96%
-0.49
34.03%
-0.38
-2.51%
-0.48
32.36%
-0.32
-17.17%
-0.49
-5.46%
-0.57
1.18%
-0.46
5.22%
-0.48
-1.66%
-0.41
32.00%
-0.54
-109.60%
-0.47
--
-0.51
--
-0.41
--
-0.80
--
4.90
--
--
--
--
--
--
--
--
--
--
淨利潤
-28.22%
-32.48M
17.23%
-23.63M
-27.99%
-29.67M
12.99%
-20.15M
-26.99%
-25.34M
-25.53%
-28.54M
-19.67%
-23.18M
-11.49%
-23.16M
-19.31%
-19.95M
-54.43%
-22.74M
-160.18%
-19.37M
-350.62%
-20.77M
-46.05%
-16.72M
-0.58%
-14.72M
324.77%
32.19M
66.23%
-4.61M
13.01%
-11.45M
-42.72%
-14.64M
-24.32%
-14.32M
-9.85%
-13.65M
資產負債率
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.00%
--
0.00%
--
0.00%
--
0.00%
--
0.00%
--
--
--
--
--
--
--
--
--
--
利潤表
營業利潤
-30.17%
-37.21M
12.21%
-27.82M
-27.47%
-34.28M
7.29%
-25.10M
-16.18%
-28.58M
-21.96%
-31.69M
-18.33%
-26.90M
-11.63%
-27.07M
-22.20%
-24.60M
-58.28%
-25.99M
-597.85%
-22.73M
-401.93%
-24.25M
-74.76%
-20.13M
-11.98%
-16.42M
77.28%
-3.26M
64.63%
-4.83M
12.51%
-11.52M
-42.62%
-14.66M
-24.10%
-14.33M
-9.32%
-13.66M
淨利潤
-28.22%
-32.48M
17.23%
-23.63M
-27.99%
-29.67M
12.99%
-20.15M
-26.99%
-25.34M
-25.53%
-28.54M
-19.67%
-23.18M
-11.49%
-23.16M
-19.31%
-19.95M
-54.43%
-22.74M
-160.18%
-19.37M
-350.62%
-20.77M
-46.05%
-16.72M
-0.58%
-14.72M
324.77%
32.19M
66.23%
-4.61M
13.01%
-11.45M
-42.72%
-14.64M
-24.32%
-14.32M
-9.85%
-13.65M
資產負債表
流動資產
83.07%
907.34M
57.36%
463.14M
49.27%
474.88M
62.52%
482.68M
55.79%
495.62M
-12.72%
294.32M
19.53%
318.13M
10.57%
297.00M
12.34%
318.13M
13.15%
337.20M
196.92%
266.15M
354.46%
268.61M
340.70%
283.18M
279.49%
298.00M
-3.30%
89.64M
-44.24%
59.10M
-9.95%
64.26M
-2.28%
78.53M
2.53%
92.70M
6.30%
106.00M
流動負債總額
-6.90%
14.16M
-17.79%
11.49M
4.10%
16.57M
-13.96%
14.65M
-31.19%
15.21M
-44.18%
13.97M
-38.54%
15.91M
40.96%
17.03M
141.66%
22.11M
128.76%
25.03M
1314.97%
25.89M
564.41%
12.08M
177.01%
9.15M
51.49%
10.94M
-74.62%
1.83M
-74.71%
1.82M
-52.65%
3.30M
31.26%
7.22M
15.42%
7.21M
35.37%
7.19M
總資產
80.64%
910.22M
53.63%
464.85M
46.17%
476.17M
60.72%
490.88M
54.07%
503.89M
-11.73%
302.57M
19.82%
325.76M
11.45%
305.43M
13.36%
327.04M
13.18%
342.78M
195.64%
271.87M
363.66%
274.04M
346.14%
288.50M
271.15%
302.87M
-1.80%
91.96M
-44.78%
59.10M
-10.77%
64.67M
-0.10%
81.60M
3.09%
93.65M
6.84%
107.03M
總負債
-2.21%
15.07M
-19.53%
11.49M
4.10%
16.57M
-13.36%
14.75M
-30.28%
15.41M
-43.05%
14.27M
-38.70%
15.91M
38.51%
17.03M
132.58%
22.11M
118.91%
25.07M
1318.63%
25.96M
576.18%
12.29M
187.92%
9.51M
24.59%
11.45M
-75.97%
1.83M
-76.25%
1.82M
-55.98%
3.30M
50.83%
9.19M
18.87%
7.62M
39.75%
7.65M
總權益
83.25%
895.15M
57.26%
453.37M
48.33%
459.60M
65.09%
476.12M
60.19%
488.47M
-9.26%
288.30M
26.00%
309.85M
10.18%
288.40M
9.30%
304.93M
9.02%
317.71M
172.84%
245.91M
356.91%
261.75M
354.65%
278.99M
302.44%
291.42M
4.76%
90.13M
-42.35%
57.29M
-5.55%
61.36M
-4.21%
72.41M
1.89%
86.03M
4.94%
99.37M
現金流量表
經營淨額
-8.64%
-18.53M
20.04%
-19.29M
7.93%
-15.84M
-8.91%
-13.28M
16.53%
-17.06M
-3.28%
-24.13M
-37.82%
-17.20M
23.29%
-12.19M
-69.60%
-20.43M
-12.08%
-23.36M
-563.94%
-12.48M
-278.34%
-15.89M
2.26%
-12.05M
-21.47%
-20.84M
84.94%
-1.88M
61.46%
-4.20M
-18.93%
-12.33M
-31.80%
-17.16M
-50.99%
-12.48M
-5.36%
-10.90M
投資淨額
-140.52%
-441.57M
2880.10%
42.53M
1602.75%
12.38M
-127.37%
-4.06M
-445.34%
-183.59M
107.98%
1.43M
-98.12%
727.00K
141.71%
14.83M
77.78%
-33.66M
-57593.55%
-17.89M
-7.49%
38.69M
-254.00%
-35.55M
-2514.24%
-151.52M
-100.58%
-31.00K
388.59%
41.82M
361.37%
23.08M
85.24%
6.28M
-70.85%
5.33M
-168.32%
-14.49M
14.10%
-8.83M
融資淨額
112.21%
463.42M
4196.15%
10.05M
-98.44%
623.00K
-132.95%
-368.00K
11991.81%
218.38M
-99.74%
234.00K
44313.33%
39.97M
362.82%
1.12M
164.04%
1.81M
-61.98%
90.27M
107.30%
90.00K
--
-425.00K
--
-2.82M
--
237.44M
-12230.00%
-1.23M
-100.00%
0.00
-100.00%
0.00
-100.00%
0.00
-101.68%
-10.00K
34708.15%
46.99M
常見問題
Enliven Therapeutics Inc的流動資產是多少?
根據Enliven Therapeutics Inc的FY2025財報,流動資產為474.88M(同比變化49.27)。
Enliven Therapeutics Inc的總資產是多少?
根據Enliven Therapeutics Inc的FY2025財報,Enliven Therapeutics Inc的總資產為476.17M(同比變化46.17)。
Enliven Therapeutics Inc的總負債是多少?
根據Enliven Therapeutics Inc的FY2025財報,Enliven Therapeutics Inc的總責任為16.57M(同比變化4.10)。
Enliven Therapeutics Inc的總權益是多少?
根據Enliven Therapeutics Inc的FY2025財報,Enliven Therapeutics Inc的總權益為459.60M(同比變化48.33)。
Enliven Therapeutics Inc的淨營業收入是多少?
根據Enliven Therapeutics Inc的FY2025財報,Enliven Therapeutics Inc的淨營業收入為-119.66M(同比變化-14.45)。
Enliven Therapeutics Inc的淨投資是多少?
根據Enliven Therapeutics Inc的FY2025財報,Enliven Therapeutics Inc的淨投資為-173.84M(同比變化-382.93)。
Enliven Therapeutics Inc的淨融資是多少?
根據Enliven Therapeutics Inc的FY2025財報,Enliven Therapeutics Inc的淨融資為218.87M(同比變化64.36)。
Enliven Therapeutics Inc的每股收益(EPS)是多少?
根據Enliven Therapeutics Inc的FY2025財報,每股收益(EPS)為-1.83(同比變化3.24)。
Enliven Therapeutics Inc的淨利潤是多少?
根據Enliven Therapeutics Inc的FY2025財報,淨利潤為-103.69M(同比變化-16.48)。
Enliven Therapeutics Inc的股東權益回報率(ROE)是多少?
根據Enliven Therapeutics Inc的FY2025財報,股東權益回報率(ROE)為-26.95(同比變化15.87)。
Enliven Therapeutics Inc的資產回報率(ROA)是多少?
根據Enliven Therapeutics Inc的FY2025財報,資產回報率(ROA)為-25.86(同比變化13.20)。
Enliven Therapeutics Inc的營業利潤是多少?
根據Enliven Therapeutics Inc的FY2025財報,營業利潤為-119.66M(同比變化-14.45)。